Showing posts with label Stem Cell. Show all posts
Showing posts with label Stem Cell. Show all posts

Tuesday, February 3, 2009

Putting A Face On The Stem Cell Argument

By MARY SWIFT
SOMETIME SOON, perhaps even this week, President Barack Obama is expected to lift federal regulations on the use of embryonic stem cells in medical research.

With recently awarded FDA approval, a California biotech firm sits poised to begin the world's first human trial that will involve injecting embryonic stem cells into the spinal cords of people who are paralyzed.

The subject spurs heated debate. Advocates believe it will throw open the door to medicine's future. Opponents say it destroys life.

At the heart of the debate, but on the sidelines of the fight, Jacob Coffron, soon to turn 18, sits in a wheelchair and breathes with the help of a ventilator.

His is the human face of the argument for embryonic stem cell research.

At 15, he fell while climbing over a fence outside his mother's Des Moines apartment.

He hasn't breathed on his own since. A month at Harborview was followed by four months at Seattle Children's, then he came home.

His mom, Amy Garnett, cares for him during the day. An aide comes in at night. Twice a week, he goes to Redmond's Pushing Boundaries, an organization that offers exercise therapy for victims of spinal cord injury.

Time has transformed him from a young teen into a near-man. He is husky and has the beginnings of a beard.

Dressed in dark sweat pants, and a black and gray T-shirt decorated with the image of a wizard and a dragon, he sat in a wheelchair in his bedroom one recent morning with a black watch cap pulled down close to his eyes. For a time he sat covered by a comforter he has to ask to have removed.

"I get so cold sometimes that I can't get warm," said Coffron, who by nature is quiet, understated -- and given to a dry sense of humor that surfaces in one-liners.

He wears metal studs in his lips and metal wires in his ears.

A poster from "Lord of the Rings" and one of the Three Stooges decorate the walls. A collection of miniature dragons sits on one shelf. Across the room, wire baskets holding an assortment of medical supplies hang on the wall next to his bed where his 12-year-old brother Cole sprawls companionably.

A silver-colored basketball -- a gift from a friend -- serves as a bittersweet reminder of a former passion."What I miss most is basketball, just playing for fun," Coffron said.

He's planning on a tattoo when he turns 18 next month, dreams about someday living in his own apartment and smiles wryly when he's asked about his "good" days.

"A good day is when they're not yelling," he said, mounting a lighthearted jab at his mother and grandmother, Jane Coffron of Kent. They laughed.

He drew more laughter when asked what he liked to eat.

"A lot," he deadpanned, flashing a fleeting smile.

After his accident, Coffron went back to Mount Rainier High briefly but eventually dropped out. At his mother's urging, he's now talking about getting a tutor and working on his GED.

His father, Terry Hornbeck, lives nearby and has a knack for treating his son like a buddy, a gift not lost on his son, who calls him "more like a friend than a dad."

Struggling to understand why an act as innocent as climbing over a fence ended so badly, he said, "I still haven't found the answer."

Behind him, Jane Coffron dabbed at her eyes. That question -- and its unfathomable answer -- is still emotional for her.

But she is steadfast in her belief that embryonic stem cell research is the key to her grandson's future.

"With it, there's hope," she said. "This is the first time that someone with his type of injury can look forward and have real hope."

As discussion swirled around him, he listened without speaking, his expression set.

Coffron's not about to kiss off hope. But right now he's busy coping with the present -- not politics.

"I don't know," he said softly when he spoke again. "I just take one day at a time."

P-I columnist Mary Swift can be reached at 206-909-9612 or swiftyk@netscape.com.
source: seattlepi.nwsource.com

Friday, January 30, 2009

A Future for Stem Cells

As President Obama continues his welcome sprint past former President George W. Bush's policies - goodbye gag rules, torture, inattention to climate change - we'd like to pause at one destination that has a particular interest for California. Last week, the Food and Drug Administration approved a request from Geron, a biotechnology company based in Menlo Park, to begin a human clinical trial testing embryonic stem cells.

The new decision's an excellent sign for stem cell researchers and those who have been desperately waiting for treatments. Though Obama has yet to lift all of Bush's restrictions on stem cell research, and the FDA's act doesn't mean that the federal government will be immediately investing much money in it, it does mean that the United States is finally ready to move forward. But it presents California's Institute for Regenerative Medicine (CIRM) - the San Francisco-based stem-cell institution formed to disperse $3 billion worth of bond money that California voters approved in 2004 - with a challenge. Now that the federal government is ready to take up the issue of stem cells, what will CIRM do with all that money?

One thing it won't be doing is giving that money back, despite the state's dire economic situation. Since the voters approved the money, there isn't much of a mechanism to stop CIRM from spending it.

That said, CIRM's main function may turn out to be positioning California as a job center and research hub for stem-cell research. (Economic research has shown that wherever the first seeds of a new industry germinate is where the hub of the entire industry tends to grow.) And provided that they realign their mission and funding goals, there's no reason why CIRM can't be as crucial to the future of stem-cell research as the federal government will be.

Fortunately, CIRM has already started to think about the future. "We have discussed doing things differently," said Don Gibbons, CIRM's chief communications officer. "For example, the National Institutes of Health tends to fund basic research, not transitional research, and the latter is what you need in order to get your product to market. So this month and next month we'll be talking about whether or not we should reallocate some of our funding to that research, so that we can help move stem cells to therapies and patients more quickly."

Gibbons added that the institute may also consider funding more "non cell-therapy uses of stem cells" that have shown great promise, such as drug development. "Vioxx wouldn't have gotten onto the market, for instance, if companies had been able to use stem cells to test for toxicity," he said.

We're heartened to see that CIRM is prepared to change with the times, and we encourage it to leverage the generosity of the California voter to form more partnerships with private companies and, one day soon, the federal government. California needs to stay a leader in the field of biotechnology.

source: sfgate.com

Saturday, January 24, 2009

Hope For Paralysed Patients As Obama Overturns Bush's Block On Stem Cell Therapy

Revolutionary human trials using stem cells to treat paralysis have been given the go-ahead.

The move offers hope to millions who are seriously injured in car crashes or sporting accidents and would otherwise not be expected to walk again.

New chapter: The potential of human embryonic stem cells will be trialled on paraplegics

The controversial experiments are to begin in the U.S. within months in what experts hail as a new era for medicine under Barack Obama’s presidency.

His predecessor George W. Bush was an opponent of stem cell research on moral grounds but President Obama has made it clear that he believes it has a large part to play in scientific developments.

US regulators cleared the way for the tests just three days after President Obama was sworn into office.

The trial will see ten people paralysed from the waist down become the first in the world to be injected with embryonic stem cells, which can be turned into any cell in the body.

Treatment will take place within the first two weeks of their injury, as it is not expected to work on long-standing problems.

Scientists will use a cocktail of chemicals to turn the embryonic stem cells into cells thought to be capable of repairing spinal cords damaged in accidents.

It is hoped that once injected into the body, the cells will replenish levels of myelin, the fatty protective sheath that insulates the nerve fibres of the brain and spinal cord.

Stocks of myelin fall when the spine is injured, causing paralysis.

Huge promise: The technology could have helped Superman actor Christopher Reeve who was confined to a wheelchair after a horse riding accident

Geron – the California-based biotech company given the green light to go ahead with the trials – has already succeeded in making paralysed rats walk again and is optimistic the treatment will work on people.

But for thousands of Britons, the trial, hailed as a potential ‘earthquake in terms of treatment of spinal injury’, offers fresh hope.

Thomas Okarma, Geron’s chief executive, said the idea ‘is not to make somebody get up and dance the next day’ but to provide an improvement that can be boosted by physiotherapy, perhaps allowing some patients to walk again – albeit shakily.

He added the injected cells also pump out substances that stimulate nerve growth – meaning they hold potential for treating strokes, multiple sclerosis and even Alzheimer’s disease.

It could also be extended to patients with neck injuries, similar to those sustained by Superman actor Christopher Reeve who was left paralysed after a riding accident in 1995.

Controversial technology: A single cell is removed from a human embryo to generate stem cells for scientific research

If the treatment is successful, it could be in widespread use in as little as four or five years, with a ‘remarkably affordable’ price tag, says Geron.

Embryonic stem cells, plucked from embryos in the first weeks of life, offer more promise than other types of stem cell, but their use is controversial, as their extraction leads to the death of the embryo, leading to protests that life is being sacrificed in
the interest of medicine.

A backlash against the change of course is growing, with Roman Catholic leaders, evangelical Christians and ethical campaigners calling the shift in stem cell policy a ‘terrible mistake’.

Although Mr Obama hasn’t yet reversed his predecessor’s ruling to free up federal funding, he has long been a strong supporter of stem cell research.

He left no doubt during his campaign that he would shift White House policy to encourage scientists to pursue the new frontier in medicine.

To do so would only require him to sign a new executive order without needing the backing of US Congress.

The U.S. move could also benefit British companies involved in stem cell research, such as Guildford-based drug developer ReNeuron.

The firm is carrying out British trials on a stroke treatment using foetal stem cells, which could potentially help 50million worldwide, and is awaiting the go-ahead to undertake similar human studies in the U.S..

Shares in ReNeuron shot up by 41?2 pence to 133?4 pence, a 49 per cent rise, on the back of the announcement, valuing the firm at ?22million.

Dr Wise Young, a spinal cord injury researcher, from Rutgers University in New Jersey, said: 'A lot of hope of the spinal cord injury community is riding on this trial.'

Opposed: Pro-life groups say the new technique involves destroying embryos. Pictured here are ampoules containing a medium for stem cell storage

Professor Chris Mason, a stem cell expert from University College London, said: 'This historic decision by the Food and Drug Administration is a pivotal milestone in the development of embryonic stem cell therapies.

'The knowledge that will be gained in this first clinical trial deploying embryonic stem cell derived material will accelerate the development of all future stem cell therapies.

'This decision is therefore very encouraging news for patients, carers and healthcare providers such as the NHS.'

But Josephine Quintavalle, of Comment on Reproductive Ethics, said: 'We still know very little about embryonic stem cells, which are notoriously unstable and with a capacity to form tumours, and if anything goes wrong the consequences will be very serious.

'The proposed therapy using embryonic stem cells does not seem to differ at all from existing therapies which use stem cells from the injured patients themselves.

'One has to ask what is the purpose of this much more controversial, experimental and risky route forward?'

Source: dailymail.co.uk